Telix Pharmaceuticals Limited announced that its prostate cancer PET imaging agent, Illuccix®? (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the SUKL for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET imaging, using a clinically validated gallium-based radiopharmaceutical.
Illuccix, after radiolabelling with gallium-68, is indicated in the Czech Republic for the detection of prostate-specific membrane antigen ("PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Prostate cancer is the most common cancer in men in the Czech Republic, with close to 8,000 new cases diagnosed annually, and a significantly higher incidence in men than either bowel (4,376 new cases) or lung cancer (3,709 new cases). Prostate cancer is also the third most common cause of cancer death in men, with over 1,600 menying from their disease in the Czech Republic in 2022.
